dna-1811955_640.jpg
logoTransvac_white.png

IMPROVING AND ACCELERATING VACCINE DEVELOPMENT IN EUROPE

Open call

TRANSVAC2, coordinated by EVI, offers free high-quality technical services at all stages of the Vaccine R&D pipeline to support the development of prophylactic and therapeutic vaccines for human and veterinary use.

Neglected Diseases

Today's Catalyst of Tomorrow's Vaccines

Emerging diseases 

Neglected and emerging infectious diseases disproportionately affect the lives of people and children living in low- and middle-income countries, causing sickness, disability and death to millions, and also represent a significant and growing threat worldwide.

Global
village

Vaccines are among the most successful and cost-effective public health tools for preventing diseases and death. Each year, more than three million lives are saved and millions more are protected from disease and disability, thanks to vaccination.

Vaccines, the way forward

EVI has a Vaccine Projects' Portfolio that addresses critical R&D challenges and opportunities in five disease areas:

Malaria is caused by Plasmodium 

parasites and spread to people through mosquitoes. 90% of all cases occur in the WHO Africa Region.

Leishmaniasis is caused by a protozoan parasite and transmitted to humans by sandflies. Over 1 billion people are at risk from leishmaniasis.

Diarrhoeal diseases are the 2nd leading cause of death in children under five. Shigella and Enterotoxigenic E. coli are major causes of diarrhoea worldwide.

Nipah virus can be transmitted from animals (pigs, bats), contaminated food or directly between people. The case fatality rate ranges from 40% to 100%.

Zika is an emerging mosquito-borne virus. Zika virus infection during pregnancy can cause infants to be born with congenital Zika syndrome.

EVI is committed to supporting vaccine development beyond individual vaccine candidates. EVI engages in initiatives aimed at creating harmonisation between stakeholders, promote networking and support access to vaccine infrastructures as well as capacity strengthening activities at the European and global level. 

EVI is committed to establishing a European vaccine R&D infrastructure to accelerate the development of prophylactic and therapeutic vaccines for human and animal health.

EVI is supporting the development and validation of non-animal approaches for testing quality of human and veterinary vaccines.

EVI seeks to create sustainable health networking, knowledge hubs and  facilitate 

cooperation of mutual benefit in health research and innovation.

EVI is working across Europe to harmonise key vaccine assays, through standardised lab procedures, preparations, and reagents, and by promoting their uptake and use.

Since its inception in 1998, EVI has succeeded in establishing and maintaining an ‘enabling environment’ that accelerates vaccine development and has developed synergies and collaborations with multiple partners, including other Product Development Partnerships (PDPs), academia, research institutions, pharma and biotechnology companies, policy makers regulatory agencies and donors.

 

In 2020, EVI supports:

10 vaccine candidates

5 disease areas

More than 100 Partners worldwide

6 vaccine candidates

in clinical development

Join European Vaccine Initiative mailing list for updates on projects, training and funding opportunities

© 2020 European Vaccine Initiative. Designed by European Vaccine Initiative